These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 11698449

  • 1. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM.
    J Immunol; 2001 Nov 15; 167(10):5758-66. PubMed ID: 11698449
    [Abstract] [Full Text] [Related]

  • 2. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
    Young KA, Chen XS, Holers VM, Hannan JP.
    J Biol Chem; 2007 Dec 14; 282(50):36614-25. PubMed ID: 17925391
    [Abstract] [Full Text] [Related]

  • 3. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD.
    J Immunol; 2001 Aug 01; 167(3):1490-9. PubMed ID: 11466369
    [Abstract] [Full Text] [Related]

  • 4. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.
    J Biol Chem; 2009 Apr 03; 284(14):9513-20. PubMed ID: 19164292
    [Abstract] [Full Text] [Related]

  • 5. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
    Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM.
    J Immunol; 2006 Jul 01; 177(1):383-94. PubMed ID: 16785534
    [Abstract] [Full Text] [Related]

  • 6. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
    Molina H, Perkins SJ, Guthridge J, Gorka J, Kinoshita T, Holers VM.
    J Immunol; 1995 May 15; 154(10):5426-35. PubMed ID: 7730644
    [Abstract] [Full Text] [Related]

  • 7. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
    Guthridge JM, Rakstang JK, Young KA, Hinshelwood J, Aslam M, Robertson A, Gipson MG, Sarrias MR, Moore WT, Meagher M, Karp D, Lambris JD, Perkins SJ, Holers VM.
    Biochemistry; 2001 May 22; 40(20):5931-41. PubMed ID: 11352728
    [Abstract] [Full Text] [Related]

  • 8. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L, Isenman DE.
    J Immunol; 2000 Oct 01; 165(7):3839-48. PubMed ID: 11034390
    [Abstract] [Full Text] [Related]

  • 9. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.
    Hannan JP, Young KA, Guthridge JM, Asokan R, Szakonyi G, Chen XS, Holers VM.
    J Mol Biol; 2005 Feb 25; 346(3):845-58. PubMed ID: 15713467
    [Abstract] [Full Text] [Related]

  • 10. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure.
    Isenman DE, Leung E, Mackay JD, Bagby S, van den Elsen JM.
    J Immunol; 2010 Feb 15; 184(4):1946-55. PubMed ID: 20083651
    [Abstract] [Full Text] [Related]

  • 11. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.
    Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.
    J Biol Chem; 2010 Aug 27; 285(35):27251-27258. PubMed ID: 20558730
    [Abstract] [Full Text] [Related]

  • 12. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).
    Prodinger WM, Schwendinger MG, Schoch J, Köchle M, Larcher C, Dierich MP.
    J Immunol; 1998 Nov 01; 161(9):4604-10. PubMed ID: 9794388
    [Abstract] [Full Text] [Related]

  • 13. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
    Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM, Hannan JP.
    J Mol Biol; 2010 Dec 10; 404(4):697-710. PubMed ID: 20951140
    [Abstract] [Full Text] [Related]

  • 14. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
    Carel JC, Myones BL, Frazier B, Holers VM.
    J Biol Chem; 1990 Jul 25; 265(21):12293-9. PubMed ID: 1695627
    [Abstract] [Full Text] [Related]

  • 15. Structure of complement receptor 2 in complex with its C3d ligand.
    Szakonyi G, Guthridge JM, Li D, Young K, Holers VM, Chen XS.
    Science; 2001 Jun 01; 292(5522):1725-8. PubMed ID: 11387479
    [Abstract] [Full Text] [Related]

  • 16. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
    Delcayre AX, Salas F, Mathur S, Kovats K, Lotz M, Lernhardt W.
    EMBO J; 1991 Apr 01; 10(4):919-26. PubMed ID: 1849076
    [Abstract] [Full Text] [Related]

  • 17. Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.
    Kulik L, Laskowski J, Renner B, Woolaver R, Zhang L, Lyubchenko T, You Z, Thurman JM, Holers VM.
    J Immunol; 2019 Dec 15; 203(12):3136-3147. PubMed ID: 31732528
    [Abstract] [Full Text] [Related]

  • 18. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2.
    Molina H, Kinoshita T, Webster CB, Holers VM.
    J Immunol; 1994 Jul 15; 153(2):789-95. PubMed ID: 8021513
    [Abstract] [Full Text] [Related]

  • 19. Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.
    Prodinger WM.
    Immunol Res; 1999 Jul 15; 20(3):187-94. PubMed ID: 10741859
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.